We believe that this discrepancy is due to different experimental design and heterogeneity of NB specimens, suggesting that further studies with a larger series of clinical tissues are warranted to investigate the exact impacts of MYCN amplification on miR-558 expression. This evidence concerns the gene MYCN and neuroblastoma.